the recently published guideline by Lehrnbecher et al [1] on antibacterial prophylaxis for prevention of febrile neutropenia in cancer children gives a weak recommendation with a moderate quality evidence not to administer systemic antibacterial prophylaxis for children undergoing allogeneic hematopoietic stem cell transplantation (HSCT). This recommendation was based mainly on a single randomized clinical trial [2], showing no effectiveness of levofloxacin compared to no prophylaxis (effectiveness 11.0% vs 17.3%; risk difference: 6.3%; p =0.06).

中文翻译：

---

在小儿异基因造血干细胞移植的植入前阶段，对发热性中性粒细胞减少症的抗菌预防无效。

Lehrnbecher 等人最近发表的指南 [1] 关于预防癌症儿童发热性中性粒细胞减少症的抗菌预防指南给出了一个中等质量证据的弱推荐，不要对接受异基因造血干细胞移植 (HSCT) 的儿童进行全身抗菌预防。该建议主要基于一项随机临床试验 [2]，显示左氧氟沙星与无预防相比没有效果（有效性 11.0% 对 17.3%；风险差异：6.3%；p = 0.06）。